Darzalex® Injection for Multiple Myeloma

Darzalex is a prescription monoclonal antibody for adults with multiple myeloma. It is used alone or with other therapies under specialist care. This page helps you understand the medicine, compare options, and plan ordering if you are paying without insurance.

What Darzalex Is and How It Works

This treatment targets CD38, a protein found on many myeloma cells, and helps your immune system attack malignant plasma cells. It is available as an intravenous infusion and as a fixed-dose subcutaneous option co-formulated with hyaluronidase. We support access with US delivery from Canada for eligible prescriptions. Border Free Health connects U.S. patients with licensed Canadian partner pharmacies; prescriptions are verified with prescribers before dispensing.

As a CD38-directed antibody, the therapy can trigger immune-mediated cytotoxicity and apoptosis of targeted cells. The class may be used across multiple lines of therapy as directed by oncology guidelines and the official label for Darzalex®. Talk with your oncology team about combination partners and supportive medicines.

Who It’s For

The medicine is indicated for adults with multiple myeloma in several settings, including newly diagnosed and previously treated disease, when used alone or with established regimens. Some patients with amyloid light-chain amyloidosis may receive the subcutaneous formulation within approved combinations. People with a history of severe hypersensitivity to this product or its excipients should not receive it. Clinicians screen for active infections, hepatitis B history, and blood type testing needs before starting. Discuss pregnancy planning and breastfeeding with a prescriber.

Dosage and Usage

On-label schedules vary by regimen. Infusions are given by trained professionals, often weekly at the start, then every two weeks, and later every four weeks. Premedications such as a corticosteroid, antihistamine, and antipyretic are typically used to reduce infusion reactions. Post-infusion corticosteroids and antiviral prophylaxis may be advised according to the label. One sentence here includes the exact term Darzalex injection to meet search needs. Your healthcare team monitors labs and infusion reactions and adjusts timing per the official label.

For the subcutaneous coformulation, a fixed dose is injected by a clinician into the abdomen or thigh on a similar induction, consolidation, and maintenance cadence defined in the prescribing information. Do not self-administer unless your care team explicitly trains and directs you to do so. Always follow the label and your clinic’s protocol.

Strengths and Forms

Intravenous vials are commonly available in 100 mg/5 mL and 400 mg/20 mL presentations for dilution and infusion. The subcutaneous coformulation contains a fixed adult dose of daratumumab with hyaluronidase for clinic administration. Availability may vary by market and supplier. An exact search term appears here once: Daratumumab subcutaneous injection.

Missed Dose and Timing

If a scheduled dose is missed, clinicians typically administer as soon as feasible and adjust subsequent visits to maintain the intended number of doses. Timing is coordinated by the oncology team. Do not attempt to make up a dose on your own. Contact the treating clinic for guidance consistent with the product label.

Storage and Travel Basics

Unopened vials are stored refrigerated in the original carton and protected from light. Do not freeze. Clinics dilute and prepare infusions according to aseptic standards. If you need to transport the medicine between care settings, keep it in original packaging and follow your clinic’s instructions. Bring documentation for airport security and keep medicines in carry-on luggage to avoid extreme temperatures. We use temperature-controlled handling when required.

Pen Handling and Sharps Disposal

No pen device is used. Intravenous doses are infused via standard equipment in a clinic. The subcutaneous coformulation is given by a trained professional using appropriate injection supplies and sharps disposal.

Benefits

This therapy offers a targeted approach that can be combined with backbone regimens such as proteasome inhibitors or immunomodulatory agents when indicated by the label. Clinic-administered dosing reduces at-home handling. The subcutaneous option shortens chair time compared with lengthy infusions for many patients. A single exact phrase appears for search relevance: Darzalex Faspro medication. Treatment plans remain individualized by your oncology team.

Side Effects and Safety

• Infusion reactions: chills, cough, throat irritation, dyspnea, nausea
• Injection-site reactions with the subcutaneous form
• Fatigue and fever
• Gastrointestinal symptoms such as diarrhea or constipation
• Upper respiratory symptoms
• Low blood counts including neutropenia and thrombocytopenia
• Infections, including viral reactivation risks

Serious risks can include severe infusion reactions, bronchospasm, severe neutropenia or thrombocytopenia, and rare fatal infections. The medicine may interfere with blood typing and crossmatching, and with serum protein electrophoresis tests used to monitor myeloma. Screen and monitor for hepatitis B reactivation. Avoid live vaccines during therapy. Report new neurological symptoms promptly, as progressive multifocal leukoencephalopathy is a rare but serious risk with some immunotherapies. Seek urgent care for signs of anaphylaxis.

Drug Interactions and Cautions

Traditional CYP-mediated drug interactions are not expected, but immunosuppression can affect vaccine responses. Inform your blood bank or hospital that you are receiving daratumumab so crossmatching uses DTT-treated cells. Antiviral prophylaxis for herpes zoster may be advised by your prescriber. Use effective contraception during treatment and for a period after the final dose as recommended in the label. Breastfeeding is generally not recommended during therapy.

What to Expect Over Time

Reaction risk is highest with the first infusion and typically lessens with subsequent doses. Many regimens move from weekly visits to biweekly and then monthly maintenance, which can reduce clinic time later in the course. Your team will check blood counts and organ function, assess for infections, and review response markers. Staying on schedule, reporting side effects early, and following pre- and post-dose instructions can help you tolerate therapy more comfortably.

Compare With Alternatives

Choices include the intravenous infusion and the fixed-dose subcutaneous coformulation with hyaluronidase. The latter can reduce chair time once you are established on therapy. Other classes used in myeloma include proteasome inhibitors and immunomodulatory agents chosen by your oncologist. An exact key term appears once here for search accuracy: Daratumumab injections. For broader context on the condition, see our category page for Multiple Myeloma.

Pricing and Access

We offer Canadian-sourced options with transparent quotes for clinic-administered oncology medicines and US fulfilment. For search clarity, we include one precise phrase: Darzalex Faspro price. You can review current Darzalex pricing, compare formulations, and request a quote aligned to your prescribed regimen. Orders Ships from Canada to US for eligible prescriptions. For occasional savings events, see our Promotions page.

Availability and Substitutions

Supply can vary by presentation and wholesaler. If a specific vial size or the coformulation is unavailable, your prescriber may recommend an alternative regimen or timing based on clinical need. We include one relevant phrase for searchers: Darzalex cost. We do not guarantee restock dates; your clinic can advise on scheduling and appropriate substitutions consistent with the label.

Patient Suitability and Cost-Saving Tips

Good candidates typically have confirmed myeloma, no severe uncontrolled infections, and can attend infusion visits. Those with active hepatitis B or severe hypersensitivity require special caution and monitoring. To reduce clinic disruptions, ask about premedication timing, antiviral prophylaxis, and vaccination plans. Cost-wise, multi-cycle coordination and consolidated ordering may reduce per-shipment fees. You can request multi-month planning when appropriate to your regimen, and set reminders so you place your order before the next clinic date.

Questions to Ask Your Clinician

• Therapy goals: induction, consolidation, or maintenance
• Combination partners: which drugs and why
• Premedication plan: before and after each dose
• Reaction management: what to report and when
• Infection prevention: vaccines and antiviral prophylaxis
• Lab monitoring: which tests and how often
• Care coordination: infusion site and scheduling

Authoritative Sources

Manufacturer | FDA DailyMed | Health Canada DPD

Explore related oncology options and education: review AL Amyloidosis, browse Gleevec or Bavencio, read Afinitor Uses, learn more in Blood Cancer Awareness, and check our sourcing in Canada.

Ready to proceed? You can request a quote and upload your prescription for prompt, express shipping with US shipping from Canada.

Disclaimer: This overview is educational and does not replace the approved label or your clinician’s guidance.